Iodopol (Sodium Iodide (131i))

Sodium Iodide (I‑131) is taken up by thyroid cells via the sodium‑iodide symporter. Once inside the gland, the isotope emits beta particles that destroy thyroid tissue and gamma photons that can be detected by imaging equipment, providing both therapeutic and diagnostic capabilities.

The dose of Iodopol is individualized and determined by the prescribing physician based on the specific indication, patient characteristics, and desired therapeutic effect. Dosing is calculated in megabecquerels (MBq) and administered under controlled conditions.

Iodopol is generally contraindicated in pregnancy because the radioactive iodine can affect fetal thyroid development. Breastfeeding should be discontinued during treatment, as iodine‑131 can be secreted in breast milk and expose the infant to radiation.

To order Iodopol, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and necessary import documentation.

Iodopol contains the same I‑131 isotope used in other branded or generic radioactive iodine preparations. Differences may lie in formulation, regulatory approvals, and supply chain logistics. Clinicians choose a product based on availability, regulatory status, and institutional preferences.

Iodopol should be stored at ambient temperature below 25 °C in its original packaging, protected from moisture and light. As a radiopharmaceutical, it must be handled in accordance with radiation safety guidelines, using appropriate shielding and monitoring.

Iodopol is administered orally as a single dose in a capsule or liquid form, depending on the product presentation. The patient swallows the dose under medical supervision, and subsequent imaging or follow‑up is performed as directed by the treating physician.

Serious risks include radiation thyroiditis, severe or permanent hypothyroidism requiring lifelong hormone replacement, bone marrow suppression leading to cytopenias, allergic reactions, and the rare possibility of secondary malignancies due to radiation exposure.

Iodopol should not be used in patients who are pregnant, breastfeeding, have a known allergy to iodine, or have uncontrolled thyroid disease where radioactive iodine therapy is contraindicated. Physicians must evaluate each patient’s medical history before prescribing.